Ventolin Evohaler
100mcg
Indicated to address airway narrowing to alleviate symptoms.
Chronic obstructive pulmonary disease (COPD) is a long-term lung condition in which the airways become inflamed and narrowed, making it progressively harder to breathe. It covers two overlapping patterns: emphysema, where the air sacs lose their elasticity, and chronic bronchitis, where the airway lining produces excess mucus. COPD does not reverse, but it can be stabilised and its daily impact significantly reduced.
100mcg
Indicated to address airway narrowing to alleviate symptoms.
100/50 · 250/50 · 500/50mcg
This inhaler is developed to target chronic obstructive pulmonary disease and is indicated to alleviate airway inflammation.
25/125 · 25/250mcg
Utilized to target asthma and COPD to support respiratory function.
15caps
Developed to alleviate chronic obstructive pulmonary disease to support better airway function and facilitate ease of breathing.
Levosalbutamol, Ipratropium Bromide
50/20mcg
Utilized to manage bronchospasm to alleviate respiratory distress.
2 · 4mg
Designed to target airway obstruction to support easier breathing.
100mcg
Indicated to relieve wheezing and formulated to target bronchospasm in asthma and respiratory conditions.
9mcg
Indicated for chronic obstructive pulmonary disease, formulated to alleviate breathing difficulties and support respiratory function in patients managing long-term lung health.
50/250mg
Formulated to alleviate symptoms of asthma and intended to target airway inflammation to support improved respiratory function.
400mg
Formulated to mitigate respiratory restriction and indicated to support ease of breathing.
400mg
Formulated to support airway patency by relaxing bronchial smooth muscle cells.
200mg
Designed to target constricted airways, promoting improved airflow and reducing breathing difficulty.
Tobacco smoking is the dominant cause globally, but across South and Southeast Asia, prolonged exposure to biomass cooking smoke, from wood, coal, and crop residue burned indoors, is a major independent risk factor, particularly among women in rural India, Indonesia, and the Philippines. Air quality in dense urban centres such as Bangkok, Jakarta, and Ho Chi Minh City adds further burden. Occupational dust and fume exposure in manufacturing and construction also contribute.
COPD typically builds slowly over years. A morning cough producing clear or yellowish mucus, gradually worsening breathlessness on exertion, and a sensation of chest tightness are the hallmark features. Wheezing is common. Many people dismiss early symptoms as a “smoker’s cough” or normal ageing, which delays diagnosis by a decade or more. Acute flare-ups, called exacerbations, produce a sudden worsening of breathlessness, increased mucus, and sometimes fever; these need prompt attention as they accelerate lung decline.
Treatment aims to open the airways, reduce inflammation, and prevent exacerbations. Short-acting bronchodilators such as salbutamol relieve breathlessness quickly during a flare. Long-acting bronchodilators like salmeterol and tiotropium provide sustained airway opening throughout the day. Inhaled corticosteroids, budesonide and fluticasone, reduce airway inflammation and are often combined with a long-acting bronchodilator in a single inhaler. Theophylline tablets remain widely used across Asia where inhaler access or cost is a barrier. Pulmonary rehabilitation, structured exercise and breathing training, improves function and quality of life beyond what medicines alone can achieve. Stopping smoking at any stage slows progression.
Seek urgent care if breathlessness becomes severe at rest, lips or fingertips turn bluish, or a flare does not improve within a day or two of starting usual treatment. Browse the full respiratory health range for available options.